WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Exchange
Industry
Zen Score
Market Cap
Price
1d %
EBITDA
P/E
D/E
ICLR
ICON PLC
NASDAQ
Diagnostics & Research
$24.81B$300.08-3.02%$1.62B36.15x0.81
FONR
FONAR CORP
NASDAQ
Diagnostics & Research
$113.14M$16.864.14%$25.75M8.92x0.28
STRR
STAR EQUITY HOLDINGS INC
NASDAQ
Diagnostics & Research
$13.91M$0.881.50%$26.87M0.55x0.16
RVTY
REVVITY INC
NYSE
Diagnostics & Research
$12.61B$102.09-0.57%$1.25B18.36x0.72
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
NYSE
Diagnostics & Research
$11.70B$227.81-4.85%$1.03B24.57x1.26
A
AGILENT TECHNOLOGIES INC
NYSE
Diagnostics & Research
$39.96B$136.37-0.81%$1.69B32.32x0.77
NEOG
NEOGEN CORP
NASDAQ
Diagnostics & Research
$2.59B$11.96-3.31%$188.76M598.00x0.46
QGEN
QIAGEN NV
NYSE
Diagnostics & Research
$9.37B$41.08-1.06%$688.56M27.39x0.61
IDXX
IDEXX LABORATORIES INC
NASDAQ
Diagnostics & Research
$40.65B$489.24-1.02%$1.22B48.11x1.20
TMO
THERMO FISHER SCIENTIFIC INC
NYSE
Diagnostics & Research
$218.01B$571.73-0.98%$11.06B36.84x1.11
ENZ
ENZO BIOCHEM INC
NYSE
Diagnostics & Research
$54.81M$1.070.94%$33.74M1.60x0.40
LH
LABORATORY CORP OF AMERICA HOLDINGS
NYSE
Diagnostics & Research
$16.68B$198.35-4.61%$1.55B41.32x1.12
MEDP
MEDPACE HOLDINGS INC
NASDAQ
Diagnostics & Research
$12.08B$389.77-1.96%$405.89M38.33x1.67
DGX
QUEST DIAGNOSTICS INC
NYSE
Diagnostics & Research
$15.04B$135.42-1.55%$1.70B17.98x1.16
CSTL
CASTLE BIOSCIENCES INC
NASDAQ
Diagnostics & Research
$535.55M$19.51-1.76%-$45.02M-9.12x0.16
SHC
SOTERA HEALTH CO
NASDAQ
Diagnostics & Research
$3.20B$11.320.44%$406.83M62.89x6.06
DHR
DANAHER CORP
NYSE
Diagnostics & Research
$182.06B$245.80-1.84%$7.54B41.24x0.56
TWST
TWIST BIOSCIENCE CORP
NASDAQ
Diagnostics & Research
$1.80B$31.081.07%-$169.85M-8.61x0.24
WAT
WATERS CORP
NYSE
Diagnostics & Research
$18.26B$308.35-0.61%$1.00B28.37x3.02
MTD
METTLER TOLEDO INTERNATIONAL INC
NYSE
Diagnostics & Research
$26.48B$1,232.91-0.20%$1.17B34.15x-23.38
SERA
SERA PROGNOSTICS INC
NASDAQ
Diagnostics & Research
$335.28M$10.342.99%-$34.76M-8.91x0.36
IQV
IQVIA HOLDINGS INC
NYSE
Diagnostics & Research
$42.47B$233.98-2.85%$3.26B31.66x3.37
EXAS
EXACT SCIENCES CORP
NASDAQ
Diagnostics & Research
$10.67B$58.79-7.04%$52.20M-52.03x1.06
XGN
EXAGEN INC
NASDAQ
Diagnostics & Research
$24.30M$1.412.17%-$18.21M-1.05x1.51
PSNL
PERSONALIS INC
NASDAQ
Diagnostics & Research
$63.13M$1.25-3.85%-$94.95M-0.56x0.74
PRPO
PRECIPIO INC
NASDAQ
Diagnostics & Research
$8.83M$6.185.38%-$4.32M-1.37x0.25
NTRA
NATERA INC
NASDAQ
Diagnostics & Research
$11.02B$91.28-0.24%-$383.28M-24.15x0.88
OLK
OLINK HOLDING AB (PUBL)
NASDAQ
Diagnostics & Research
$2.87B$23.072.85%-$20.05M-92.28x0.20
FLGT
FULGENT GENETICS INC
NASDAQ
Diagnostics & Research
$596.59M$20.03-3.42%-$134.12M-3.56x0.09
DRIO
DARIOHEALTH CORP
NASDAQ
Diagnostics & Research
$43.28M$1.47-2.00%-$54.38M-0.76x0.66
ACRS
ACLARIS THERAPEUTICS INC
NASDAQ
Diagnostics & Research
$84.40M$1.191.71%-$87.99M-0.94x0.26
GH
GUARDANT HEALTH INC
NASDAQ
Diagnostics & Research
$2.09B$17.16-5.19%-$433.31M-4.01x10.26
STIM
NEURONETICS INC
NASDAQ
Diagnostics & Research
$104.74M$3.52-6.13%-$22.76M-3.35x2.39
NEO
NEOGENOMICS INC
NASDAQ
Diagnostics & Research
$1.77B$13.85-1.28%-$8.37M-19.79x0.79
DMTK
DERMTECH INC
NASDAQ
Diagnostics & Research
$20.25M$0.59-4.72%-$95.04M-0.19x1.13
BNR
BURNING ROCK BIOTECH LTD
NASDAQ
Diagnostics & Research
$87.04M$0.853.53%N/A-0.96x0.35
OCX
ONCOCYTE CORP
NASDAQ
Diagnostics & Research
$20.19M$2.44-0.81%-$26.05M-0.65x2.41
RDNT
RADNET INC
NASDAQ
Diagnostics & Research
$3.35B$48.850.37%$265.49M977.00x2.98
BGLC
BIONEXUS GENE LAB CORP
NASDAQ
Diagnostics & Research
$10.48M$0.59-0.34%-$2.49M-3.24x0.18
LAB
STANDARD BIOTOOLS INC
NASDAQ
Diagnostics & Research
$684.68M$2.36-2.48%-$65.66M-2.51x-1.08
PRE
PRENETICS GLOBAL LTD
NASDAQ
Diagnostics & Research
$60.21M$4.973.76%N/A-0.89x0.21
APDN
APPLIED DNA SCIENCES INC
NASDAQ
Diagnostics & Research
$4.24M$5.004.69%-$5.89M-0.45x1.37
XWEL
XWELL INC
NASDAQ
Diagnostics & Research
$7.53M$1.800.00%-$24.16M-0.27x1.39
BDSX
BIODESIX INC
NASDAQ
Diagnostics & Research
$122.15M$1.260.00%-$37.10M-1.97x20.64
CDNA
CAREDX INC
NASDAQ
Diagnostics & Research
$391.45M$7.56-5.26%-$182.19M-2.14x0.79
MDXH
MDXHEALTH SA
NASDAQ
Diagnostics & Research
$6.68M$2.47-0.80%-$20.47M-0.15x16.92
CHEK
CHECK-CAP LTD
NASDAQ
Diagnostics & Research
$13.28M$2.272.25%-$19.08M-0.75x0.06
ME
23ANDME HOLDING CO
NASDAQ
Diagnostics & Research
$221.66M$0.46-1.71%-$490.64M-0.41x0.61
NDRA
ENDRA LIFE SCIENCES INC
NASDAQ
Diagnostics & Research
$2.67M$0.24-6.92%-$9.78M-0.15x0.19
ULS
UL SOLUTIONS INC
NYSE
Diagnostics & Research
N/A$33.89-0.18%$519.00M26.07x3.15
PRPH
PROPHASE LABS INC
NASDAQ
Diagnostics & Research
$89.32M$4.95-2.17%-$14.83M-5.05x0.86
AWH
ASPIRA WOMEN's HEALTH INC
NASDAQ
Diagnostics & Research
$40.49M$3.28-3.53%-$16.50M-1.81x-3.65
OPK
OPKO HEALTH INC
NASDAQ
Diagnostics & Research
$850.33M$1.22-0.81%-$65.62M-4.88x0.45
NOTV
INOTIV INC
NASDAQ
Diagnostics & Research
$110.64M$4.29-8.14%$59.57M-3.30x2.29
VNRX
VOLITIONRX LTD
NYSEMKT
Diagnostics & Research
$73.04M$0.8911.25%-$33.68M-1.78x-4.70
ISPC
ISPECIMEN INC
NASDAQ
Diagnostics & Research
$2.54M$0.280.72%-$9.02M-0.23x0.62
GENE
GENETIC TECHNOLOGIES LTD
NASDAQ
Diagnostics & Research
$503.22k$2.18-3.11%N/A-0.73x0.76
MYGN
MYRIAD GENETICS INC
NASDAQ
Diagnostics & Research
$1.62B$17.98-3.49%-$186.10M-5.65x0.46
BIAF
BIOAFFINITY TECHNOLOGIES INC
NASDAQ
Diagnostics & Research
$27.75M$2.41-1.63%-$7.63M-2.65x0.69
PMD
PSYCHEMEDICS CORP
NASDAQ
Diagnostics & Research
$14.59M$2.54-3.97%-$768.00k-3.53x0.85
ILMN
ILLUMINA INC
NASDAQ
Diagnostics & Research
$19.23B$121.05-1.48%-$608.00M-16.49x0.76
MYNZ
MAINZ BIOMED NV
NASDAQ
Diagnostics & Research
$18.14M$0.86-4.67%-$24.62M-0.53x3.74
TRIB
TRINITY BIOTECH PLC
NASDAQ
Diagnostics & Research
$14.03M$1.830.00%N/AN/A-3.48
MMA
ALTA GLOBAL GROUP LTD
NYSEMKT
Diagnostics & Research
N/A$3.161.94%-$16.12M-0.60x-0.55
CNTG
CENTOGENE NV
NASDAQ
Diagnostics & Research
$13.25M$0.484.12%-$44.39M-0.30x-5.72
TTOO
T2 BIOSYSTEMS INC
NASDAQ
Diagnostics & Research
$15.10M$2.74-0.72%-$42.53M-0.14x-2.24

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the top diagnostic & research stock with a Zen Score of 50, which is 22 points higher than the diagnostic & research industry average of 28. It passed 16 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 47.66% over the past year, overperforming other diagnostic & research stocks by 50 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 15.45% from Icon's current stock price of $300.08.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the second best diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 8.56% over the past year, overperforming other diagnostic & research stocks by 11 percentage points.

3. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 14.03% over the past year, overperforming other diagnostic & research stocks by 16 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.12%, which is 2 percentage points higher than the diagnostic & research industry average of 1.38%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.13%, which is 1 percentage points higher than the diagnostic & research industry average of 1.38%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.45%, which is the same as the diagnostic & research industry average of 1.38%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.46% in the last day, and up 3.15% over the last week. Laboratory Of America Holdings was the among the top losers in the diagnostics & research industry, dropping -4.61% yesterday.

Laboratory Corp shares are trading lower. The company reported Q1 financial results.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Icon has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Icon's stock has gained 47.66% in the past year. It has overperformed other stocks in the diagnostic & research industry by 50 percentage points.

2. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 14.03% in the past year. It has overperformed other stocks in the diagnostic & research industry by 16 percentage points.

3. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -56.85% in the past year. It has underperformed other stocks in the diagnostic & research industry by -54 percentage points.

Are diagnostic & research stocks a good buy now?

48.94% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 11.37% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.32x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.